胃癌的免疫治疗及疗效预测进展
Advances in Immunotherapy and Efficacy Prediction for Gastric Cancer
摘要: 目的：了解胃癌免疫治疗及疗效预测最新研究进展。方法：检索近年来国内外有关胃癌免疫治疗及疗效预测研究的相关文献并进行综述。结果：胃癌免疫治疗研究最多的是免疫检查点抑制剂，尤其是针对抗程序性细胞死亡蛋白-1 (PD-1)/程序性死亡配体-1 (PD-L1)抗体和细胞毒性T淋巴细胞相关抗原4 (CTLA-4抗体)三种类型的研究较多。目前研究火热的免疫PET、CT、MRI和氟脱氧葡萄糖PET的新应用在疗效预测方面都有极大的应用价值。结论：随着免疫治疗研究的深入，胃癌免疫治疗的策略也在不断改进，免疫治疗过程中疗效预测愈发显得重要，针对相应的治疗方法筛选适宜的患者及采用精准治疗手段可进一步让胃癌患者生存获益。
Abstract: Objective: To recognize the latest research progress of gastric cancer immunotherapy and efficacy evaluation. Methods: The domestic and international literature on immunotherapy and efficacy evaluation for GC in recent years were retrieved and reviewed. Results: The most immunotherapy researched was ICIs, especially for programmed death protein-1 (PD-1)/programmed death protein ligand 1 (PD-L1), cytotoxic T lymphocyte associated antigen 4 (CTLA-4 antibody). At present, the new applications of immune PET, CT, MRI and fluorodeoxyglucose PET are of great application value in the efficacy evaluation. Conclusion: With the further study of immunotherapy research, the strategy of immunotherapy for gastric cancer is also constantly improving, and the efficacy evaluation in the process of immunotherapy is becoming more and more important. Screening suitable patients for the corresponding treatment methods and adopting precise treatment methods can further benefit gastric cancer patients.
文章引用：陈进瑜, 付大秀, 杨银蕊, 李振辉, 王关顺. 胃癌的免疫治疗及疗效预测进展[J]. 临床医学进展, 2024, 14(9): 983-992. https://doi.org/10.12677/acm.2024.1492556

参考文献

[1] Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. [Google Scholar] [CrossRef] [PubMed]
[2] Lu, L., Mullins, C.S., Schafmayer, C., Zeißig, S. and Linnebacher, M. (2021) A Global Assessment of Recent Trends in Gastrointestinal Cancer and Lifestyle-Associated Risk Factors. Cancer Communications, 41, 1137-1151. [Google Scholar] [CrossRef] [PubMed]
[3] Guan, W., He, Y. and Xu, R. (2023) Gastric Cancer Treatment: Recent Progress and Future Perspectives. Journal of Hematology & Oncology, 16, Article No. 57. [Google Scholar] [CrossRef] [PubMed]
[4] Li, K., Zhang, A., Li, X., Zhang, H. and Zhao, L. (2021) Advances in Clinical Immunotherapy for Gastric Cancer. Biochimica et Biophysica Acta—Reviews on Cancer, 1876, Article 188615. [Google Scholar] [CrossRef] [PubMed]
[5] Pennathur, A., Gibson, M.K., Jobe, B.A. and Luketich, J.D. (2013) Oesophageal Carcinoma. The Lancet, 381, 400-412. [Google Scholar] [CrossRef] [PubMed]
[6] Qiu, H., Cao, S. and Xu, R. (2021) Cancer Incidence, Mortality, and Burden in China: A Time-Trend Analysis and Comparison with the United States and United Kingdom Based on the Global Epidemiological Data Released in 2020. Cancer Communications, 41, 1037-1048. [Google Scholar] [CrossRef] [PubMed]
[7] Wagner, A.D., Syn, N.L., Moehler, M., Grothe, W., Yong, W.P., Tai, B., et al. (2017) Chemotherapy for Advanced Gastric Cancer. Cochrane Database of Systematic Reviews, 2017, CD004064. [Google Scholar] [CrossRef] [PubMed]
[8] Dercle, L., Sun, S., Seban, R., Mekki, A., Sun, R., Tselikas, L., et al. (2023) Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. Radiology, 306, 32-46. [Google Scholar] [CrossRef] [PubMed]
[9] Bai, Y., Xie, T., Wang, Z., Tong, S., Zhao, X., Zhao, F., et al. (2022) Efficacy and Predictive Biomarkers of Immunotherapy in Epstein-Barr Virus-Associated Gastric Cancer. Journal for ImmunoTherapy of Cancer, 10, e004080. [Google Scholar] [CrossRef] [PubMed]
[10] Song, J., Wei, R., Huo, S., Gao, J. and Liu, X. (2022) Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer. Frontiers in Immunology, 13, Article 920512. [Google Scholar] [CrossRef] [PubMed]
[11] Li, Q., Zhou, Z., Lu, J., Luo, H., Wang, S., Peng, Y., et al. (2022) PD-L1P146R Is Prognostic and a Negative Predictor of Response to Immunotherapy in Gastric Cancer. Molecular Therapy, 30, 621-631. [Google Scholar] [CrossRef] [PubMed]
[12] Mellman, I., Coukos, G. and Dranoff, G. (2011) Cancer Immunotherapy Comes of Age. Nature, 480, 480-489. [Google Scholar] [CrossRef] [PubMed]
[13] Kono, K. (2018) Advances in Cancer Immunotherapy for Gastroenterological Malignancy. Annals of Gastroenterological Surgery, 2, 244-245. [Google Scholar] [CrossRef] [PubMed]
[14] Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. (2011) Ipilimumab Plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 364, 2517-2526. [Google Scholar] [CrossRef] [PubMed]
[15] Bagchi, S., Yuan, R. and Engleman, E.G. (2021) Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223-249. [Google Scholar] [CrossRef] [PubMed]
[16] Ahmed, H., Mahmud, A.R., Shahriar, A., Biswas, P., Shimul, M.E.K., et al. (2023) Role of T Cells in Cancer Immunotherapy: Opportunities and Challenges. Cancer Pathogenesis and Therapy, 1, 116-126. [Google Scholar] [CrossRef] [PubMed]
[17] Muro, K., Chung, H.C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., et al. (2016) Pembrolizumab for Patients with Pd-L1-Positive Advanced Gastric Cancer (KEYNOTE-012): A Multicentre, Open-Label, Phase 1b Trial. The Lancet Oncology, 17, 717-726. [Google Scholar] [CrossRef] [PubMed]
[18] Shitara, K., Özgüroğlu, M., Bang, Y., Di Bartolomeo, M., Mandalà, M., Ryu, M., et al. (2018) Pembrolizumab versus Paclitaxel for Previously Treated, Advanced Gastric or Gastro-Oesophageal Junction Cancer (KEYNOTE-061): A Randomized, Open-Label, Controlled, Phase 3 Trial. The Lancet, 392, 123-133. [Google Scholar] [CrossRef] [PubMed]
[19] Boku, N., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H.C., et al. (2021) Nivolumab in Previously Treated Advanced Gastric Cancer (ATTRACTION-2): 3-Year Update and Outcome of Treatment Beyond Progression with Nivolumab. Gastric Cancer, 24, 946-958. [Google Scholar] [CrossRef] [PubMed]
[20] Moehler, M., Dvorkin, M., Boku, N., Özgüroğlu, M., Ryu, M., Muntean, A.S., et al. (2021) Phase III Trial of Avelumab Maintenance after First-Line Induction Chemotherapy versus Continuation of Chemotherapy in Patients with Gastric Cancers: Results from JAVELIN Gastric 100. Journal of Clinical Oncology, 39, 966-977. [Google Scholar] [CrossRef] [PubMed]
[21] Sznol, M. and Melero, I. (2021) Revisiting Anti-Ctla-4 Antibodies in Combination with PD-1 Blockade for Cancer Immunotherapy. Annals of Oncology, 32, 295-297. [Google Scholar] [CrossRef] [PubMed]
[22] Janjigian, Y.Y., Bendell, J.C., Calvo, E., Kim, J.W., Ascierto, P.A., Sharma, P., et al. (2016) Checkmate-032: Phase I/II, Open-Label Study of Safety and Activity of Nivolumab (nivo) Alone or with Ipilimumab (ipi) in Advanced and Metastatic (A/M) Gastric Cancer (GC). Journal of Clinical Oncology, 34, 4010-4010. [Google Scholar] [CrossRef] 
[23] Moehler, M.H., Cho, J.Y., Kim, Y.H., Kim, J.W., Di Bartolomeo, M., Ajani, J.A., et al. (2016) A Randomized, Open-Label, Two-Arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab (ipi) versus Best Supportive Care (BSC) Following First-Line (1L) Chemotherapy in Patients with Unresectable, Locally Advanced/metastatic (A/M) Gastric or Gastro-Esophageal Junction (G/GEJ) Cancer. Journal of Clinical Oncology, 34, 4011-4011. [Google Scholar] [CrossRef] 
[24] Kelly, R.J., Lee, J., Bang, Y., Almhanna, K., Blum-Murphy, M., Catenacci, D.V.T., et al. (2020) Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 26, 846-854. [Google Scholar] [CrossRef] [PubMed]
[25] Homann, N., Lorenzen, S., Schenk, M., Thuss-Patience, P.C., Goekkurt, E., Hofheinz, R.D., et al. (2020) Interim Safety Analysis of the DANTE Trial: Perioperative Atezolizumab in Combination with FLOT versus FLOT Alone in Patients with Resectable Esophagogastric Adenocarcinoma—A Randomized, Open-Label Phase II Trial of the German Gastric Group at the AIO and Sakk. Journal of Clinical Oncology, 38, 4549-4549. [Google Scholar] [CrossRef] 
[26] Bang, Y., Muro, K., Fuchs, C.S., Golan, T., Geva, R., Hara, H., et al. (2017) KEYNOTE-059 Cohort 2: Safety and Efficacy of Pembrolizumab (pembro) Plus 5-Fluorouracil (5-FU) and Cisplatin for First-Line (1L) Treatment of Advanced Gastric Cancer. Journal of Clinical Oncology, 35, 4012-4012. [Google Scholar] [CrossRef] 
[27] Shitara, K., Van Cutsem, E., Bang, Y., Fuchs, C., Wyrwicz, L., Lee, K., et al. (2020) Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer. JAMA Oncology, 6, 1571-1580. [Google Scholar] [CrossRef] [PubMed]
[28] Janjigian, Y.Y., Shitara, K., Moehler, M., Garrido, M., Salman, P., Shen, L., et al. (2021) First-line Nivolumab Plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (Checkmate 649): A Randomized, Open-Label, Phase 3 Trial. The Lancet, 398, 27-40. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, F., Wei, X.L., Wang, F.H., Xu, N., Shen, L., Dai, G.H., et al. (2019) Safety, Efficacy and Tumor Mutational Burden as a Biomarker of Overall Survival Benefit in Chemo-Refractory Gastric Cancer Treated with Toripalimab, a PD-1 Antibody in Phase Ib/II Clinical Trial Nct02915432. Annals of Oncology, 30, 1479-1486. [Google Scholar] [CrossRef] [PubMed]
[30] Xu, J., Bai, Y., Xu, N., Li, E., Wang, B., Wang, J., et al. (2020) Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research, 26, 4542-4550. [Google Scholar] [CrossRef] [PubMed]
[31] Biagioni, A., Skalamera, I., Peri, S., Schiavone, N., Cianchi, F., Giommoni, E., et al. (2019) Update on Gastric Cancer Treatments and Gene Therapies. Cancer and Metastasis Reviews, 38, 537-548. [Google Scholar] [CrossRef] [PubMed]
[32] Wang, R., Dang, M., Harada, K., Han, G., Wang, F., Pool Pizzi, M., et al. (2021) Single-Cell Dissection of Intratumoral Heterogeneity and Lineage Diversity in Metastatic Gastric Adenocarcinoma. Nature Medicine, 27, 141-151. [Google Scholar] [CrossRef] [PubMed]
[33] Noh, S.H., Park, S.R., Yang, H., Chung, H.C., Chung, I., Kim, S., et al. (2014) Adjuvant Capecitabine Plus Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): 5-Year Follow-Up of an Open-Label, Randomized Phase 3 Trial. The Lancet Oncology, 15, 1389-1396. [Google Scholar] [CrossRef] [PubMed]
[34] Dercle, L., Ammari, S., Champiat, S., Massard, C., Ferté, C., Taihi, L., et al. (2016) Rapid and Objective CT Scan Prognostic Scoring Identifies Metastatic Patients with Long-Term Clinical Benefit on Anti-Pd-1/-L1 Therapy. European Journal of Cancer, 65, 33-42. [Google Scholar] [CrossRef] [PubMed]
[35] Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., et al. (2018) Association of the Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 4, 351-357. [Google Scholar] [CrossRef] [PubMed]
[36] Castello, A., Toschi, L., Rossi, S., Mazziotti, E. and Lopci, E. (2020) The Immune-Metabolic-Prognostic Index and Clinical Outcomes in Patients with Non-Small Cell Lung Carcinoma under Checkpoint Inhibitors. Journal of Cancer Research and Clinical Oncology, 146, 1235-1243. [Google Scholar] [CrossRef] [PubMed]
[37] Dercle, L., McGale, J., Sun, S., Marabelle, A., Yeh, R., Deutsch, E., et al. (2022) Artificial Intelligence and Radiomics: Fundamentals, Applications, and Challenges in Immunotherapy. Journal for ImmunoTherapy of Cancer, 10, e005292. [Google Scholar] [CrossRef] [PubMed]
[38] Dercle, L., Fronheiser, M., Lu, L., Du, S., Hayes, W., Leung, D.K., et al. (2020) Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics. Clinical Cancer Research, 26, 2151-2162. [Google Scholar] [CrossRef] [PubMed]
[39] He, B., Dong, D., She, Y., Zhou, C., Fang, M., Zhu, Y., et al. (2020) Predicting Response to Immunotherapy in Advanced Non-Small-Cell Lung Cancer Using Tumor Mutational Burden Radiomic Biomarker. Journal for ImmunoTherapy of Cancer, 8, e000550. [Google Scholar] [CrossRef] [PubMed]
[40] Sun, R., Limkin, E.J., Vakalopoulou, M., Dercle, L., Champiat, S., Han, S.R., et al. (2018) A Radiomics Approach to Assess Tumour-Infiltrating CD8 Cells and Response to Anti-Pd-1 or Anti-Pd-L1 Immunotherapy: An Imaging Biomarker, Retrospective Multicohort Study. The Lancet Oncology, 19, 1180-1191. [Google Scholar] [CrossRef] [PubMed]
[41] Sun, R., Sundahl, N., Hecht, M., Putz, F., Lancia, A., Rouyar, A., et al. (2020) Radiomics to Predict Outcomes and Abscopal Response of Patients with Cancer Treated with Immunotherapy Combined with Radiotherapy Using a Validated Signature of CD8 Cells. Journal for ImmunoTherapy of Cancer, 8, e001429. [Google Scholar] [CrossRef] [PubMed]
[42] Mekki, A., Dercle, L., Lichtenstein, P., Nasser, G., Marabelle, A., Champiat, S., et al. (2019) Machine Learning Defined Diagnostic Criteria for Differentiating Pituitary Metastasis from Autoimmune Hypophysitis in Patients Undergoing Immune Checkpoint Blockade Therapy. European Journal of Cancer, 119, 44-56. [Google Scholar] [CrossRef] [PubMed]
[43] Eche, T., Schwartz, L.H., Mokrane, F. and Dercle, L. (2021) Toward Generalizability in the Deployment of Artificial Intelligence in Radiology: Role of Computation Stress Testing to Overcome Underspecification. Radiology: Artificial Intelligence, 3, e210097. [Google Scholar] [CrossRef] [PubMed]
[44] Petrova, M.P., Donev, I.S., Radanova, M.A., Eneva, M.I., Dimitrova, E.G., Valchev, G.N., et al. (2020) Sarcopenia and High NLR Are Associated with the Development of Hyperprogressive Disease after Second-Line Pembrolizumab in Patients with Non-Small-Cell Lung Cancer. Clinical and Experimental Immunology, 202, 353-362. [Google Scholar] [CrossRef] [PubMed]
[45] Sinigaglia, M., Assi, T., Besson, F.L., Ammari, S., Edjlali, M., Feltus, W., et al. (2019) Imaging-Guided Precision Medicine in Glioblastoma Patients Treated with Immune Checkpoint Modulators: Research Trend and Future Directions in the Field of Imaging Biomarkers and Artificial Intelligence. EJNMMI Research, 9, Article No. 78. [Google Scholar] [CrossRef] [PubMed]
[46] Chen, A., Mokrane, F., Schwartz, L.H., Morschhauser, F., Stamatoullas, A., Schiano de Colella, J., et al. (2019) Early 18f-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab. Journal of Nuclear Medicine, 61, 649-654. [Google Scholar] [CrossRef] [PubMed]
[47] Mokrane, F., Chen, A., Schwartz, L.H., Morschhauser, F., Stamatoullas, A., Schiano de Colella, J., et al. (2020) Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma. Radiology, 295, 651-661. [Google Scholar] [CrossRef] [PubMed]
[48] Lopci, E., Hicks, R.J., Dimitrakopoulou-Strauss, A., Dercle, L., Iravani, A., Seban, R.D., et al. (2022) Joint EANM/SNMMI/ANZSNM Practice Guidelines/Procedure Standards on Recommended Use of [18F]FDG PET/CT Imaging during Immunomodulatory Treatments in Patients with Solid Tumors Version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 49, 2323-2341. [Google Scholar] [CrossRef] [PubMed]
[49] Wachsmann, J.W., Ganti, R. and Peng, F. (2017) Immune-Mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. Academic Radiology, 24, 111-115. [Google Scholar] [CrossRef] [PubMed]
[50] Karantanis, D., Bogsrud, T.V., Wiseman, G.A., Mullan, B.P., Subramaniam, R.M., Nathan, M.A., et al. (2007) Clinical Significance of Diffusely Increased 18F-FDG Uptake in the Thyroid Gland. Journal of Nuclear Medicine, 48, 896-901. [Google Scholar] [CrossRef] [PubMed]
[51] Costa, L.B., Queiroz, M.A., Barbosa, F.G., Nunes, R.F., Zaniboni, E.C., Ruiz, M.M., et al. (2021) Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. RadioGraphics, 41, 120-143. [Google Scholar] [CrossRef] [PubMed]
[52] Eshghi, N., Garland, L.L., Nia, E., Betancourt, R., Krupinski, E. and Kuo, P.H. (2018) 18F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer. Journal of Nuclear Medicine Technology, 46, 260-264. [Google Scholar] [CrossRef] [PubMed]
[53] Iravani, A., Osman, M.M., Weppler, A.M., Wallace, R., Galligan, A., Lasocki, A., et al. (2020) FDG PET/CT for Tumoral and Systemic Immune Response Monitoring of Advanced Melanoma during First-Line Combination Ipilimumab and Nivolumab Treatment. European Journal of Nuclear Medicine and Molecular Imaging, 47, 2776-2786. [Google Scholar] [CrossRef] [PubMed]
[54] Bensch, F., van der Veen, E.L., Lub-de Hooge, M.N., Jorritsma-Smit, A., Boellaard, R., Kok, I.C., et al. (2018) 89Zr-atezolizumab Imaging as a Non-Invasive Approach to Assess Clinical Response to PD-L1 Blockade in Cancer. Nature Medicine, 24, 1852-1858. [Google Scholar] [CrossRef] [PubMed]
[55] Farwell, M.D., Gamache, R.F., Babazada, H., Hellmann, M.D., Harding, J.J., Korn, R., et al. (2021) Cd8-Targeted PET Imaging of Tumor Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Human Study of 89zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody. Journal of Nuclear Medicine, 63, 720-726. [Google Scholar] [CrossRef] [PubMed]
[56] Pandit-Taskar, N., Postow, M.A., Hellmann, M.D., Harding, J.J., Barker, C.A., O’Donoghue, J.A., et al. (2019) First-In-humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Mini-Body in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. Journal of Nuclear Medicine, 61, 512-519. [Google Scholar] [CrossRef] [PubMed]
[57] Namavari, M., Chang, Y., Kusler, B., Yaghoubi, S., Mitchell, B.S. and Gambhir, S.S. (2010) Synthesis of 2’-Deoxy-2’-[18F]Fluoro-9-Β-D-Arabinofuranosylguanine: A Novel Agent for Imaging T-Cell Activation with Pet. Molecular Imaging and Biology, 13, 812-818. [Google Scholar] [CrossRef] [PubMed]

为你推荐